Intestinal protein expression profile identifies inflammatory bowel disease and predicts relapse

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 5, 2013, Pages 917-925

  Shen, Jun ^a,b   Qiao, Yuqi ^a,b   Ran, Zhihua ^a,b   Wang, Tianrong ^a,b   Xu, Jiangtao ^c   Feng, Jinsun ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c NATIONAL ENGINEERING CENTER FOR BIOCHIP AT SHANGHAI   (China)

Author keywords

Classification; Crohn's disease; Relapse; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; PROTEOME; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ADULT; BIOSYNTHESIS; CLASSIFICATION; CLUSTER ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASE; MALE; METABOLISM; PROGNOSIS; RECURRENT DISEASE; TISSUE MICROARRAY;

ADULT; BIOLOGICAL MARKERS; CLUSTER ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASES; MALE; PROGNOSIS; PROTEOME; RECURRENCE; TISSUE ARRAY ANALYSIS; TNF RECEPTOR-ASSOCIATED FACTOR 2;

EID: 84882945350     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Carpenter HA, Talley NJ. The importance of clinicopathological correlation in the diagnosis of inflammatory conditions of the colon: histological patterns with clinical implications. Am J Gastroenterol 2000; 95: 878-896.
2. Schulze HA, Häsler R, Mah N, Lu T, Nikolaus S, Costello CM, Schreiber S. From model cell line to in vivo gene expression: disease-related intestinal gene expression in IBD. Genes Immun 2008; 9: 240-248.
3. Henriksen M, Jahnsen J, Lygren I, Sauar J, Schulz T, Stray N, Vatn MH, Moum B, Ibsen Study Group. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study). Scand J Gastroenterol 2006; 41: 1037-1043.
4. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho GT, Satsangi J, Bloom S; IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607.
5. Casellas F, Barreiro de Acosta M, Iglesias M, Robles V, Nos P, Aguas M, Riestra S, de Francisco R, Papo M, Borruel N. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2012; 24: 762-769.
6. Geboes K, Colombel JF, Greenstein A, Jewell DP, Sandborn WJ, Vatn MH, Warren B, Riddell RH; Pathology Task Force of the International Organization of Inflammatory Bowel Diseases. Indeterminate colitis: a review of the conceptwhat's in a name?. Inflamm Bowel Dis 2008; 14: 850-857.
7. Ghosh S, D'Haens G, Feagan BG, Silverberg MS, Szigethy EM. What do changes in inflammatory bowel disease management mean for our patients?. J Crohns Colitis 2012; 6 Suppl 2: S243-S249.
8. Moum B. Medical treatment: does it influence the natural course of inflammatory bowel disease?. Eur J Intern Med 2000; 11: 197-203.
9. Romberg-Camps MJ, Dagnelie PC, Kester AD, Hesselink-van de Kruijs MA, Cilissen M, Engels LG, Van Deursen C, Hameeteman WH, Wolters FL, Russel MG, Stockbrügger RW. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009; 104: 371-383.
10. D'Incà R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, Oliva L, Sturniolo GC. Can calprotectin predict relapse risk in inflammatory bowel disease?. Am J Gastroenterol 2008; 103: 2007-2014.
11. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
12. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic or unnecessary toys?. Gut 2006; 55: 426-431.
13. Foley KF, Kao P. Biomarkers for in?.ammatory bowel disease. Clin Lab Sci 2007; 20: 84-88.
14. Wang Q, Gong L, Dong R, Qiao Q, He XL, Chu YK, Du XL, Yang Y, Zang L, Nan J, Lin C, Lu JG. Tissue microarray assessment of selenoprotein p expression in gastric adenocarcinoma. J Int Med Res 2009; 37: 169-174.
15. Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S, Syrjänen K, Collan Y, Pyrhönen S. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res 2008; 28: 3865-3870.
16. Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-512.
17. Baron JH, Connell AM, Lennard JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964; 1: 89-92.
18. Fernebro E, Dictor M, Bendahl PO, Fernö M, Nilbert M. Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 2002; 126: 702-705.
19. Walker RA. Quantification of immunohistochemistry-- issues concerning methods, utility and semiquantitative assessment I. Histopathology 2006; 49: 406-410.
20. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adélaïde J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, Birnbaum D, Bertucci F. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005; 65: 767-779.
21. Papachristou GI, Plevy S. Novel biologics in inflammatory bowel disease. Gastroenterol Clin North Am 2004; 33: 251-269.
22. Zhang T, Song B, Zhu W, Xu X, Gong QQ, Morando C, Dassopoulos T, Newberry RD, Hunt SR, Li E. An ileal Crohn's disease gene signature based on whole human genome expression profiles of disease unaffected ileal mucosal biopsies. PLoS One 2012; 7: e37139.
23. Roda G, Caponi A, Benevento M, Nanni P, Mezzanotte L, Belluzzi A, Mayer L, Roda A. New proteomic approaches for biomarker discovery in inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1239-1246.
24. da Silva JG, De Brito T, Cintra Damião AO, Laudanna AA, Sipahi AM. Histologic study of colonic mucosa in patients with chronic diarrhea and normal colonoscopic findings. J Clin Gastroenterol 2006; 40: 44-48.
25. Warren BF, Edwards CM, Travis SP. 'Microscopic colitis': classification and terminology. Histopathology 2002; 40: 374-376.
26. Paski SC, Wightman R, Robert ME, Bernstein CN. The importance of recognizing increased cecal inflammation in health and avoiding the misdiagnosis of nonspecific colitis. Am J Gastroenterol 2007; 102: 2294-2299.
27. Quinn PG, Binion DG, Connors PJ. The role of endoscopy in in?.ammatory bowel disease. Med Clin North Am 1994; 78: 1331-1352.
28. Liu AY, Vêncio RZ, Page LS, Ho ME, Loprieno MA, True LD. Bladder expression of CD cell surface antigens and cell-type-specific transcriptomes. Cell Tissue Res 2012; 348: 589-600.
29. Nakano H, Sakon S, Koseki H, Takemori T, Tada K, Matsumoto M, Munechika E, Sakai T, Shirasawa T, Akiba H, Kobata T, Santee SM, Ware CF, Rennert PD, Taniguchi M, Yagita H, Okumura K. Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation. Proc Natl Acad Sci U S A 1999; 96: 9803-9808.
30. Ha H, Han D, Choi Y. TRAF-mediated TNFR-family signaling. Curr Protoc Immunol 2009 Nov; Chapter 11: Unit11.9D.
31. Sun SC. Non-canonical NF-?.B signaling pathway. Cell Res 2011; 21: 71-85.
32. Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population- based cohort. Gastroenterology 2007; 133: 412-422.
33. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-468.
34. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007; 25: 247-255.
35. Geboes K. Pathology of inflammatory bowel diseases (IBD): variability with time and treatment. Colorectal Dis 2001; 3: 2-12.
36. Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Cosenza L, Staiano A, Troncone R. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008; 40: 547-553.
37. Peterson CG, Sangfelt P, Wagner M, Hansson T, Lettesjö H, Carlson M. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest 2007; 67: 810-820.
38. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103: 162-169.
39. Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T, Zeuzem S, Meuer SC, Stallmach A. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin- 27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 2005; 11: 16-23.
40. Pardi DS, Sandborn WJ. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?. Gut 2005; 54: 321-322.
41. Consigny Y, Modigliani R, Colombel JF, Dupas JL, Lémann M, Mary JY; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 2006; 12: 551-557.
42. Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54: 364-388.
43. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
44. So T, Soroosh P, Eun SY, Altman A, Croft M. Antigen-independent signalosome of CARMA1, PKC?., and TNF receptor-associated factor 2 (TRAF2) determines NF-?.B signaling in T cells. Proc Natl Acad Sci U S A 2011; 108: 2903- 2908.
45. Bhattacharyya S, Dudeja PK, Tobacman JK. Tumor necrosis factor alpha-induced inflammation is increased but apoptosis is inhibited by common food additive carrageenan. J Biol Chem 2010; 285: 39511-39522.